Chloroquine and Amodiaquine for Treatment of Malaria in Children

• Status: Completed
• Trial end date: 2004-05-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will evaluate the efficacy of the treatment recommended by the National Malaria Programme in Guinea-Bissau as compared to a higher dose of chloroquine and to another anti-malarial drug, amodiaquine. The genetic basis of the parasites for developing resistance will be examined. Children coming to Bandim Health Centre with symptoms of malaria and a positive malaria test will be included. The children will be visited and malaria films will be obtained weekly until day 35. In case of a reappearance of parasites the children will be re-treated with sulfadoxine/pyrimethamine.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bandim Health Project
• Treatments: Amodiaquine; Chloroquine; Chloroquine diphosphate

Criteria

Inclusion Criteria:

• Patients < 15 years of age presenting at Bandim Health Centre

• Symptoms suggestive of malaria

• At least 20 P. falciparum parasites per 200 leukocytes in a thick film

• Live in Bandim (to enable follow-up)

Exclusion Criteria:

• Severely ill children considered needing the services of a hospital by the medical doctor in charge

• Stated medication with other antimalarials within one week prior to treatment

• Previous idiosyncratic reactions to any of the study drugs